trending Market Intelligence /marketintelligence/en/news-insights/trending/Uv9sy0JHikeIyBaMwxzQrA2 content esgSubNav
In This List

GW Pharmaceuticals submits EMA application for epilepsy disorder drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


GW Pharmaceuticals submits EMA application for epilepsy disorder drug

GW Pharmaceuticals plc submitted its marketing authorization application to the European Medicines Agency for Epidiolex as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

Dravet syndrome is a severe infantile-onset epileptic syndrome resulting in moderate to severe intellectual and developmental disabilities, and Lennox-Gastaut syndrome is characterized by multiple types of seizures and intellectual disability.

GW Pharmaceuticals in October completed the submission of its rolling application to the U.S. Food and Drug Administration for the same indication.

The application for Epidiolex is supported by data from three phase 3 studies, each of which met their primary endpoint.